ChemRoutes Corporation is a private e-Discovery based drug discovery technology provider working at the interface of chemistry, chemical biology, fragment based drug discovery and nanotechnology. It was established in 1999 and is headquartered in Edmonton, Alberta, Canada
The pharmaceutical development model is transforming – driven by patent expiration on blockbuster drugs, the rise of generic products and increased pressure to fill pipelines. Pharmaceutical and biotech companies are focusing on late stage compound development and clinical trial. This has resulted in a gap in early stage drug discovery. The new ChemDiscovery Platform™ serves as a novel and cost effective technology-driven solution: “turning molecules into medicine.”
ChemRoutes Corporation has a thorough understanding of the drug discovery and development process, state of the art facilities and an experienced scientific advisory board. We focus on early stage drug discovery to pre-clinical research. Our proprietary and novel small molecule based scaffolds, building blocks, chemical arrays and new chemical target research spans infectious, neurodegenerative and metabolic diseases, pain and inflammation, and oncology areas. We have consistently delivered results, leading to global partnerships with over 60 major pharmaceutical, agrochemical and biotech companies accessing our novel chemistry driven platforms for new molecular targets and biochemical pathways.
.